MarketInOut Stock Screener Log In | Sign Up

Jaguar Health Inc

IEX • Healthcare • Biotechnology • Quote as of 10/30/2026
Jaguar Health Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization3.96 mln
Float1.82 mln
Earnings Date11/17/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-6.11
Highly reliable

Relative Strength

0 / 100
Severely lagging

Debt / Equity

2.77
Very high leverage

Pre-Tax Margin

-133%
Severely loss-making

ROE

-549
Deeply negative

Business Description

Jaguar Health is a San Francisco-based pharmaceutical company that develops plant-derived medicines to treat gastrointestinal conditions in both humans and animals. Its flagship product, Mytesi, is an approved treatment for diarrhea in HIV/AIDS patients, while Canalevia-CA1 addresses the same condition in dogs undergoing chemotherapy. The company is advancing a broader pipeline of treatments targeting conditions such as irritable bowel syndrome, short bowel syndrome, and cancer-related diarrhea across multiple clinical trials.

Key Fundamentals

EPS-4,013
ROE-549
RPS1,241
ROIC-59.13
ROA-87.62
Interest Cover-28.98
EBITDA, mln-33.89
EV / EBITDA-0.07
EV / EBIT-0.06
Revenue, mln27.82
EV / Revenue0.08

Quote Details

Last 1.62
Change -0.44 (-21.36%)
Open 2.00
Volume 342,307
Turnover 554,537
Average Volume 1,875,388

Financial Ratios

Pre-Tax Profit Margin-133
Leverage Ratio5.17
Current Ratio0.69
Price / Book0.11
Debt / Equity2.77
Price / Sales0.14

Financial Strength

Altman Z-Score-19.38
Piotroski F-Score 4 / 9
Beneish M-Score-6.11
Short Ratio0.02
Short % of Float7.22

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -20.59% 2 / 100   
1 Month -58.14% 1 / 100   
2 Months -88.98% 1 / 100   
6 Months -98.39% 0 / 100   
1 Year -99.85% 0 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog